A Phase I/II Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
Considering participating in a START clinical trial?
Study Summary
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
To evaluate CRN09682 in patients with SST2-expressing neuroendocrine tumors (NETs) and other solid tumors, validating the company’s intent to extend its endocrine expertise into GPCR-targeted oncology indications.
- * Have a histological diagnosis of metastatic or locally advanced inoperable NET, NEC, or other solid tumors that have confirmed radiological progression.
- * Have one or more measurable disease location per RECIST version 1.1.
- * Have a tumor that expresses SSR confirmed by SSR imaging.
- * Have an ECOG performance status of 0, 1, or 2.
- * Have tumor progression while undergoing a course of PRRT or within 6 months of completing PRRT.
- * Have brain metastases unless asymptomatic and stable for at least one month for participants with SCLC or LCLC or at least 3 months for participants with other non-NET solid tumors.
- * Use of anticancer agents within specified intervals prior to the first dose of study drug.
- * Had surgery, chemoembolization, or radiofrequency ablation within 90 days prior to first dose of study drug.
- * Prior participation in any intervention clinical study within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.
- * Participants with carcinoid syndrome.
- * Secondary malignancy: participants who have any other malignancy known to be active or treated within 3 years of the start of screening, with the exception of treated cervical intraepithelial neoplasia, superficial (noninvasive) bladder cancer, and non-melanoma skin cancer.
- * Have prior treatment with MMAE.
- * Have hypersensitivity or history of anaphylactic reaction to octreotide, other SSAs, and/or MMAE.
Clinical Study Information for Healthcare Providers
By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.